Suppr超能文献

V2 血管加压素受体突变:基于个体分子生物学的未来个体化治疗。

V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology.

机构信息

Department of Anesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary.

Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.

出版信息

Front Endocrinol (Lausanne). 2023 May 24;14:1173601. doi: 10.3389/fendo.2023.1173601. eCollection 2023.

Abstract

The diluting and concentrating function of the kidney plays a crucial role in regulating the water homeostasis of the body. This function is regulated by the antidiuretic hormone, arginine vasopressin through the type 2 vasopressin receptor (V2R), allowing the body to adapt to periods of water load or water restriction. Loss-of-function mutations of the V2R cause X-linked nephrogenic diabetes insipidus (XNDI), which is characterized by polyuria, polydipsia, and hyposthenuria. Gain-of-function mutations of the V2R lead to nephrogenic syndrome of inappropriate antidiuresis disease (NSIAD), which results in hyponatremia. Various mechanisms may be responsible for the impaired receptor functions, and this review provides an overview of recent findings about the potential therapeutic interventions in the light of the current experimental data.

摘要

肾脏的稀释和浓缩功能在调节身体的水稳态方面起着至关重要的作用。这种功能通过抗利尿激素,精氨酸加压素通过 2 型血管加压素受体(V2R)来调节,使身体能够适应水负荷或水限制期。V2R 的功能丧失性突变导致 X 连锁肾性尿崩症(XNDI),其特征是多尿、多饮和低尿。V2R 的获得性功能突变导致肾性尿崩症不合时宜的抗利尿激素综合征(NSIAD),导致低钠血症。各种机制可能导致受体功能受损,本综述根据当前的实验数据,就潜在的治疗干预措施提供了最新发现的概述。

相似文献

1
V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology.
Front Endocrinol (Lausanne). 2023 May 24;14:1173601. doi: 10.3389/fendo.2023.1173601. eCollection 2023.
2
[Nephrogenic syndrome of inappropriate antidiuresis].
Pan Afr Med J. 2019 Apr 29;32:210. doi: 10.11604/pamj.2019.32.210.6006. eCollection 2019.
5
V2 vasopressin receptor mutations.
Vitam Horm. 2020;113:79-99. doi: 10.1016/bs.vh.2019.08.012. Epub 2019 Sep 13.
7
V2R mutations and nephrogenic diabetes insipidus.
Prog Mol Biol Transl Sci. 2009;89:15-29. doi: 10.1016/S1877-1173(09)89002-9. Epub 2009 Oct 7.
8
Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
Clin Endocrinol (Oxf). 2009 Sep;71(3):388-93. doi: 10.1111/j.1365-2265.2008.03513.x. Epub 2008 Dec 18.

引用本文的文献

1
Ciliary G-Protein Coupled Receptor Signaling in Polycystic Kidney Disease.
Int J Mol Sci. 2025 May 22;26(11):4971. doi: 10.3390/ijms26114971.
2
Association of Elevated Serum Aldosterone Concentrations in Pregnancy with Hypertension.
Biomedicines. 2023 Nov 1;11(11):2954. doi: 10.3390/biomedicines11112954.

本文引用的文献

1
Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial.
Clin J Am Soc Nephrol. 2023 Jan 1;18(1):36-46. doi: 10.2215/CJN.0000000000000022.
2
Genetic basis of nephrogenic diabetes insipidus.
Mol Cell Endocrinol. 2023 Jan 15;560:111825. doi: 10.1016/j.mce.2022.111825. Epub 2022 Nov 30.
5
Nephrogenic Syndrome of Inappropriate Antidiuresis Mimicking Hyporeninemic Hypoaldosteronism: Case Report of Two Infants.
J Clin Res Pediatr Endocrinol. 2023 May 29;15(2):214-219. doi: 10.4274/jcrpe.galenos.2021.2021.0191. Epub 2021 Oct 14.
7
Treatment and long-term outcome in primary nephrogenic diabetes insipidus.
Nephrol Dial Transplant. 2020 Dec 26. doi: 10.1093/ndt/gfaa243.
9
Germline-Derived Gain-of-Function Variants of Gs-Coding Gene Identified in Nephrogenic Syndrome of Inappropriate Antidiuresis.
J Am Soc Nephrol. 2019 May;30(5):877-889. doi: 10.1681/ASN.2018121268. Epub 2019 Apr 8.
10
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1153-1161. doi: 10.2215/CJN.01520218. Epub 2018 Jul 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验